Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Brimonidine/Ketotifen Ophthalmic Solution
NCT05815758Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brimonidine tartrate + sodium hyaluronate, ketotifen in allergic conjunctivitis (AC), sponsored by Bausch + Lomb. Started Apr 2023; status: completed.
02
Drugs
brimonidine tartrate + sodium hyaluronateketotifen
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05815758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815758.